Thomas Shrader Analyst PerformanceEquity Research Analyst at BTIG ResearchThomas Shrader is a stock analyst at BTIG Research focused in the medical sector, covering 31 publicly traded companies. Over the past year, Thomas Shrader has issued 67 stock ratings, including strong buy, buy, and hold recommendations. While full access to Thomas Shrader's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Thomas Shrader's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings94 Last 10 YearsBuy Recommendations92.55% 87 Buy RatingsCompanies Covered31 Unique Companies Ratings Distribution94RatingsDistribution of strong buy, buy, hold, and sell ratings by Thomas Shrader.RatingPercentageCount Strong Buy1.1%1 ratings Buy91.5%86 ratings Hold7.4%7 ratings Sell0.0%0 ratingsOut of 94 total stock ratings issued by Thomas Shrader at BTIG Research, the majority (91.5%) have been Buy recommendations, followed by 7.4% Hold and 1.1% Strong Buy.Best & Worst CallsBest Call0000.0%OVIDMar 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%ESPRJul 2015Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ93.5% of companies on NASDAQ29 companiesNYSE6.5% of companies on NYSE2 companiesThomas Shrader, an analyst at BTIG Research, currently covers 31 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical29 companies93.5%Manufacturing2 companies6.5%Thomas Shrader of BTIG Research specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE22 companies71.0%MED - DRUGS6 companies19.4%Miscellaneous1 company3.2%MEDICAL SERVICES1 company3.2%PHARMACEUTICAL PREPARATIONS1 company3.2% About Thomas ShraderThomas Shrader, PhD, CFA, is a Managing Director and Healthcare Analyst at BTIG. He provides coverage of the biotechnology sector, with a focus on large and smidcap companies. Previously, he was a Biotechnology Research Analyst at Stifel. Earlier in his career, Mr. Shrader was on the Biochemistry Faculty at the Albert Einstein College of Medicine. He earned a BA from The Johns Hopkins University, a PhD from Yale University and was a Helen Hay Whitney Fellow at the Massachusetts Institute of Technology.Follow on LinkedIn Thomas Shrader's Ratings History at BTIG Research Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsBIOABioAge Labs5/13/2026Initiated Coverage$18.19$40.00Buy$0.0000.00% ROICMPSCompass Pathways5/13/2026Reiterated Rating$10.67$14.00Buy$0.0000.00% ROIBIOABioAge Labs5/13/2026Initiated Coverage$19.14$40.00Buy$0.0000.00% ROIHROWHarrow5/12/2026Reiterated Rating$29.03$63.00Buy$0.0000.00% ROIDNLIDenali Therapeutics5/11/2026Reiterated Rating$19.62$39.00Buy$0.0000.00% ROISTOKStoke Therapeutics5/11/2026Reiterated Rating$32.89$39.00Buy$0.0000.00% ROIACIUAC Immune5/4/2026Reiterated Rating$2.98$8.00Buy$0.0000.00% ROINTHINeonc Technologies4/24/2026Initiated Coverage$4.79$15.00Buy$0.0000.00% ROINTHINeonc Technologies4/24/2026Initiated Coverage$4.78$15.00Buy$0.0000.00% ROICMPSCompass Pathways4/20/2026Reiterated Rating$9.22$14.00Buy$0.0000.00% ROITomorrow's Stock of the Day (Ad)Looking for better stock ideas? Sign-up to receive The Early Bird Stock of the Day. Each day, MarketBeat's team of expert research analysts identifies one compelling stock and provides both a bull case and a bear case for each company.Get The Early Bird's Stock of the Day (Free)HROWHarrow4/17/2026Reiterated Rating$40.65$63.00Buy$0.0000.00% ROIDRUGBright Minds Biosciences3/30/2026Reiterated Rating$70.10$147.00Buy$0.0000.00% ROIABOSAcumen Pharmaceuticals3/26/2026Reiterated Rating$2.53$8.00Buy$0.0000.00% ROIOVIDOvid Therapeutics3/26/2026Reiterated Rating$2.46$4.00Buy$0.0000.00% ROIDNLIDenali Therapeutics3/25/2026Boost Price Target$22.47$38.00Buy$0.0000.00% ROINRXPNRx Pharmaceuticals3/24/2026Reiterated Rating$1.92$25.00Buy$0.0000.00% ROISTOKStoke Therapeutics3/19/2026Reiterated Rating$31.02$39.00Buy$0.0000.00% ROIHROWHarrow3/18/2026Reiterated Rating$35.21$63.00Buy$0.0000.00% ROIALDXAldeyra Therapeutics3/17/2026Reiterated Rating$1.24Buy$0.0000.00% ROIACIUAC Immune3/16/2026Reiterated Rating$3.02$8.00Buy$0.0000.00% ROIABOSAcumen Pharmaceuticals3/16/2026Boost Price Target$3.34$8.00Buy$0.0000.00% ROIALECAlector3/10/2026Upgrade$2.19$6.00Buy$0.0000.00% ROIIRDOpus Genetics3/2/2026Boost Price Target$4.16$12.00Buy$0.0000.00% ROIDNLIDenali Therapeutics3/2/2026Boost Price Target$21.18$36.00Buy$0.0000.00% ROIIVVDInvivyd2/26/2026Reiterated Rating$1.71$10.00Buy$0.0000.00% ROIPCVXVaxcyte2/25/2026Boost Price Target$62.97$89.00Buy$0.0000.00% ROINRXPNRx Pharmaceuticals2/18/2026Reiterated Rating$1.85$25.00Buy$0.0000.00% ROIANROAlto Neuroscience2/17/2026Boost Price Target$17.00$28.00Buy$0.0000.00% ROIDRUGBright Minds Biosciences2/17/2026Reiterated Rating$77.90$147.00Buy$0.0000.00% ROIDNLIDenali Therapeutics2/6/2026Reiterated Rating$20.02$32.00Buy$0.0000.00% ROIIRDOpus Genetics1/28/2026Reiterated Rating$2.83$7.00Buy$0.0000.00% ROIABOSAcumen Pharmaceuticals1/27/2026Boost Price Target$2.08$7.00Buy$0.0000.00% ROIIVVDInvivyd1/21/2026Reiterated Rating$2.24Buy$0.0000.00% ROIIRDOpus Genetics1/20/2026Initiated Coverage$2.10$7.00Buy$0.0000.00% ROINVAXNovavax1/20/2026Reiterated Rating$8.61$19.00Buy$0.0000.00% ROIIRDOpus Genetics1/20/2026Initiated Coverage$2.26$7.00Buy$0.0000.00% ROINRXPNRx Pharmaceuticals1/15/2026Reiterated Rating$2.15$25.00Buy$0.0000.00% ROIDRUGBright Minds Biosciences1/6/2026Boost Price Target$98.64$147.00Buy$0.0000.00% ROIALECAlector1/5/2026Upgrade$1.69Strong-Buy$0.0000.00% ROIIVVDInvivyd12/22/2025Initiated Coverage$2.30$10.00Buy$0.0000.00% ROIRead this or regret it forever (Ad)Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.Don’t be left behind. Click here now.IVVDInvivyd12/22/2025Initiated Coverage$2.82$10.00Buy$0.0000.00% ROIDNLIDenali Therapeutics12/5/2025Reiterated Rating$20.11$32.00Buy$0.0000.00% ROINRXPNRx Pharmaceuticals12/3/2025Reiterated Rating$2.27$25.00Buy$0.0000.00% ROIBHVNBiohaven11/18/2025Reiterated Rating$8.27$16.00Buy$0.0000.00% ROIANROAlto Neuroscience11/17/2025Initiated Coverage$12.01$27.00Buy$0.0000.00% ROICOYACoya Therapeutics11/13/2025Boost Price Target$5.94$16.00Buy$0.0000.00% ROIPCVXVaxcyte11/10/2025Reiterated Rating$41.65$85.00Buy$0.0000.00% ROIALDXAldeyra Therapeutics11/10/2025Reiterated Rating$4.69$9.00Buy$0.0000.00% ROIBHVNBiohaven11/6/2025Lower Price Target$8.31$16.00Buy$0.0000.00% ROISTOKStoke Therapeutics11/5/2025Reiterated Rating$25.34$39.00Buy$0.0000.00% ROIACIUAC Immune11/4/2025Reiterated Rating$3.40$8.00Buy$0.0000.00% ROIALECAlector10/22/2025Downgrade$3.21Neutral$0.0000.00% ROIARCTArcturus Therapeutics10/22/2025Lower Price Target$11.02$23.00Buy$0.0000.00% ROIGANXGain Therapeutics10/15/2025Reiterated Rating$2.04$9.00Buy$0.0000.00% ROICMPSCompass Pathways10/13/2025Boost Price Target$6.41$14.00Buy$0.0000.00% ROISTOKStoke Therapeutics10/13/2025Boost Price Target$30.34$39.00Buy$0.0000.00% ROICOYACoya Therapeutics9/30/2025Reiterated Rating$5.66$15.00Buy$0.0000.00% ROIALECAlector9/25/2025Reiterated Rating$3.16$5.00Buy$0.0000.00% ROIHROWHarrow9/24/2025Reiterated Rating$48.85$63.00Buy$0.0000.00% ROIDRUGBright Minds Biosciences9/8/2025Initiated Coverage$42.24$72.00Buy$0.0000.00% ROIGANXGain Therapeutics9/8/2025Reiterated Rating$1.76$9.00Buy$0.0000.00% ROIACIUAC Immune9/8/2025Reiterated Rating$2.28$8.00Buy$0.0000.00% ROIBHVNBiohaven8/19/2025Boost Price Target$15.71$60.00Buy$0.0000.00% ROISTOKStoke Therapeutics8/18/2025Set Price Target$18.26$28.00Buy$0.0000.00% ROIHROWHarrow8/14/2025Boost Price Target$36.50$63.00Buy$0.0000.00% ROIVRNAVerona Pharma PLC American Depositary Share7/10/2025Downgrade$104.77Hold$0.0000.00% ROIINMBINmune Bio7/1/2025Reiterated Rating$2.31Neutral$0.0000.00% ROIALDXAldeyra Therapeutics4/7/2025Lower Price Target$1.76$9.00Buy$0.0000.00% ROIOVIDOvid Therapeutics3/24/2025Lower Price Target$0.44$4.00Buy$0.0000.00% ROIARCTArcturus Therapeutics1/28/2025Initiated Coverage$16.43$41.00Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel NicolausRaymond James FinancialBMO Capital Markets Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
